Literature DB >> 11164487

Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma.

C G Anastassopoulou1, G Touloumi, A Katsoulidou, H Hatzitheodorou, M Pappa, D Paraskevis, M Lazanas, P Gargalianos, A Hatzakis.   

Abstract

HIV-1 RNA measurements from 84 plasma specimens obtained with the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays (Chiron Diagnostics, Emeryville, CA) and with the AMPLICOR HIV-1 MONITOR Test, version 1.5 with ultra-sensitive specimen preparation (Roche Diagnostic Systems, Inc., Branchburg, NJ) were compared. The absolute RNA values of tested specimens differed significantly between bDNA 2.0 and bDNA 3.0 or Monitor v1.5 measurements (Wilcoxon signed-rank test P<0.001). Results generated with bDNA 3.0 or with Monitor v1.5 were approximately twofold greater than those generated with bDNA 2.0, with smaller differences at higher HIV-1 RNA levels and greater differences at RNA levels below 1000 copies per ml. Although highly correlated (r=0.92 and 0.86, respectively), viral load data generated with bDNA 2.0 and either bDNA 3.0 or Monitor v1.5 were in poor agreement. Concordant results (difference in log(10) copies per ml <0.5) were found at frequencies of 80% for bDNA 2.0 and bDNA 3.0 and only at 58.5% for bDNA 2.0 and Monitor v1.5. In contrast, bDNA 3.0 and Monitor v1.5 measurements were highly correlated (r=0.96) and in good agreement (92.7%).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164487     DOI: 10.1016/s0166-0934(00)00245-7

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

Review 1.  The handling of missing data in molecular epidemiology studies.

Authors:  Manisha Desai; Jessica Kubo; Denise Esserman; Mary Beth Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

2.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.

Authors:  Isabelle Desombere; Hans Van Vlierberghe; Sibyl Couvent; Filip Clinckspoor; Geert Leroux-Roels
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.